Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.

The unit – the first of its kind that Oxford has developed in the Americas – will work on developing new drugs and vaccines to drive ongoing human health research. It will also focus on training a new generation of clinical researchers by offering Master’s, PhD studentships and courses in infectious diseases, clinical development and vaccinology.

The COVID-19 pandemic has brought the risk of life-threatening infectious diseases into sharp focus, and both the University and their Brazilian counterparts initially aim to drive research to better prepare and respond to health risks by focussing on COVID-19 vaccines and treatments before potentially branching out into other clinical areas.

The unit is also a culmination of a strong relationship the University has built with Brazilian researchers during the pandemic.

Professor Sir Andrew Pollard said: 'Brazilian researchers and the public of Brazil made an extraordinary contribution to the clinical trials of the Oxford-AstraZeneca vaccine, with more than 10,000 volunteers taking part. We are delighted to forge stronger links with the local research teams to improve human health under the leadership of Professor Clemens.'

The UK Government supports the establishment of an Oxford-Brazil collaborative centre for research and training in Brazil, while other prestigious institutions such as the University of Siena’s Institute for Global Health and International Vaccines Institute in South Korea are also partners.

Marcelo Queiroga, the Brazilian Minister of Health, said: 'This collaboration between leading Brazilian researchers and the team at the University of Oxford behind the Oxford-AstraZeneca vaccine is a major step forward in ensuring we are better prepared for future health threats and train the next generation of experts across our nations.'

 Article source: https://www.ox.ac.uk/news/2021-11-01-oxford-work-brazil-establish-clinical-research-hub

Similar stories

New survey launched to explore the acceptability of the Gonococcal Controlled Human Infection Model in UK men.

Researchers at the University of Oxford have launched a new mixed methods study to explore the acceptability of the Gonococcal Controlled Human Infection Model (GC-CHIM) in UK men.

Oxford Ebola vaccine manufactured and shipped in record time by SII

More than 40,000 doses of Oxford’s Ebola vaccine have been manufactured by SII (Serum Institute of India) in just 60 days and doses shipped to Uganda.

From running COVID-19 trials to researching respiratory diseases - Daniela Ferreira discusses her journey from Brazil to Oxford

Daniela Ferreira, Professor of Mucosal Immunity and Infection at the Oxford Vaccine Group, Department of Paediatrics, has so much enthusiasm for her work on respiratory infections and vaccinology, you would be very hard-pressed not to want her to succeed

It’s not just Covid: the triple threat that could overwhelm the NHS this winter - Andrew Pollard

A severe flu outbreak or new coronavirus variant could prove catastrophic for a health service already on its knees

Novel all-in-one vaccine developed to tackle future coronavirus threats

Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.